“精研十余载,成就慰心愿”,2025年4月,喜闻国内首款IL-12/IL-23“双靶向”单克隆抗体药物上市的消息,昭衍安评人为之振奋。此为我国创新生物药中首款需要进行非人灵长类(NHP)动物生殖毒性试验的项目,也是昭衍实验室继“十二五重大新药创制平台建设项目”的技术开发后,首次开展的新药猴生殖毒性评价项目。该药的获批上市,也标志着国内首例NHP生殖毒性试验通过了国家药品监督管理局的严格检验,完美...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.